Yahoo

New Seborrheic Dermatitis Treatment Calms the Skin Condition

Add Yahoo as a preferred source to see more of our stories on Google. It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes ...

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...
Healio

Roflumilast foam outperforms vehicle in seborrheic dermatitis treatment

Please provide your email address to receive an email when new articles are posted on . On Dec. 16, 2023, roflumilast foam 0.3% was FDA-approved for the treatment of seborrheic dermatitis. The results ...
AOL

Seborrheic Dermatitis vs Dandruff: What’s Causing Your Flakes?

This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let's talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...
Nasdaq

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

WESTLAKE VILLAGE, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Healio

Roflumilast foam safe, effective treatment of seborrheic dermatitis

Please provide your email address to receive an email when new articles are posted on . 73.8% of roflumilast-treated patients achieved the primary endpoint compared with 40.9% of the vehicle group.
Monthly Prescribing Reference

Zoryve Topical Foam Approved for Seborrheic Dermatitis

Credit: Arcutis. Zoryve topical foam is a once-daily steroid-free formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. The Food and Drug Administration (FDA) has approved ...
Nasdaq

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

Arcutis Biotherapeutics, Inc. ARQT announced that the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients ...
Today

I’m a dermatologist. These 5 viral skin care hacks actually work

Dermatologists often discourage trying to treat skin conditions at home with a mishmash of ingredients. But, if you have patches of itchy, red skin, there's one at-home remedy that might actually work ...
Medscape

FDA to Review Roflumilast Foam for Seborrheic Dermatitis

The US Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for roflumilast foam 0.3% for treating seborrheic dermatitis in patients ages 9 years and older. If approved ...
Medscape

Roflumilast Foam Effectively Eases Seborrheic Dermatitis

After 8 weeks, eight out of ten people with seborrheic dermatitis saw their symptoms cleared or improved with once-daily treatment with roflumilast 0.3% foam, according to the results of the phase 3 ...